FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Petition Seeks Risk-Based Peptide Framework

[ Price : $8.95]

A biopharmaceutical expert petitions FDA to establish a risk-based regulatory framework for peptide therapeutics.

RWE, 510(k) TTD Discussed in MDUFA 6 Reauthorization

[ Price : $8.95]

At a 12/11/2025 MDUFA 6 reauthorization meeting, FDA presented its views on changes involving using real-world evidence and calcul...

9 Observations on Pharmathen International FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with nine observations from an inspection at Greeces Pharmathen International.

CRL for Outlooks Wet AMD Drug

[ Price : $8.95]

FDA issues a complete response letter to Outlook Therapeutics seeking additional confirmatory evidence for its BLA for Lytenava to...

Priority Review for Axsome Alzheimer's Agitation Drugs

[ Price : $8.95]

FDA grants priority review for an Axsome Therapeutics sNDA to treat Alzheimers disease agitation.

CGMP Violations at Absolutely Natural

[ Price : $8.95]

FDA warns Melbourne, FL-based Absolutely Natural about CGMP violations in its production of finished drugs.

Makary Touts Less Oversight on Wearables

[ Price : $8.95]

FDA commissioner Marty Makary promotes limited regulatory scrutiny of many wearable devices and software tools, a significant poli...

Class 1 Abiomed Impella Correction

[ Price : $8.95]

FDA says the Abiomed 6/23/2025 correction to user instructions for its Automated Impella Controllers was Class 1.

Agebox Illegally Selling Unapproved iKids-Growth Drugs

[ Price : $8.95]

FDA warns Wilington, DE-based Agebox about selling misbranded unapproved new drugs.